MAUI | Cancer severity | Mean (SD) | Median | Effect size |
|---|
EQ-5D-3 L |
| | OPMD | 0.78 (0.19) | 0.79 | |
| | Stage 1 | 0.76 (0.17) | 0.78 | 0.025 |
| | Stage 2 | 0.69 (0.28) | 0.77 | 0.092 |
| | Stage 3 | 0.57 (0.22) | 0.56 | 0.174 |
| | Stage 4 | 0.48 (0.46) | 0.59 | 0.158 |
EORTC-8D |
| | OPMD | 0.84 (0.17) | 0.90 | |
| | Stage 1 | 0.83 (0.14) | 0.85 | 0.011 |
| | Stage 2 | 0.73 (0.23) | 0.78 | 0.120 |
| | Stage 3 | 0.65 (0.21) | 0.63 | 0.109 |
| | Stage 4 | 0.61 (0.32) | 0.72 | 0.061 |
- Stage 1 -The cancer is less than 2 cm in size, and has not spread to lymph nodes in the area; Stage 2 - The cancer is more than 2 cm in size, but less than 4 cm, and has not spread to lymph nodes in the area; Stage 3 - The cancer is bigger than 4 cm but has not spread to any lymph nodes or other parts of the body; Stage 4- The cancer is either greater than 4 cm in largest diameter or is of any size but has metastasised to regional lymph nodes; SD = standard deviation; Kruskal-Wallis test was used to determine the significance of difference between severity classes, p < 0.05; Wilcoxon matched paired rank test was used to test the significance between utility scores for each severity class, p < 0.05; MAUI = multi attribute utility instrument
